TY - T1的石棉相关肺癌是rarely associated with ALK, ROS1 and RET rearrangements JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02605-2017 VL - 51 IS - 3 SP - 1702605 AU - Uguen, Marie AU - Dewitte, Jean-Dominique AU - Loddé, Brice AU - Marcorelles, Pascale AU - Uguen, Arnaud Y1 - 2018/03/01 UR - //www.qdcxjkg.com/content/51/3/1702605.abstract N2 - Lung cancer remains the main cause of cancer death. In addition to smoking, exposure to occupational carcinogens constitutes a major risk for lung cancer. Among occupational cancers, asbestos-related ones are the most frequent, accounting for about 5–7% of lung cancers. A better understanding of the molecular pathways implicated in the progression of cancer has greatly improved the therapeutic management of patients with advanced lung cancers, especially nonsmall cell lung cancer (NSCLC) of the adenocarcinoma subtype. Indeed, several therapies targeting the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)/ROS1 pathways are now approved to treat patients with advanced EGFR-mutated or ALK/ROS1-rearranged NSCLC, respectively. While EGFR and ALK alterations are mainly encountered in NSCLC of nonsmokers, other biomarkers are more frequent in smoking patients, such as KRAS mutations, and are of prognostic interest. Nevertheless, the frequencies of the different biomarkers analysed daily for the therapeutic management of patients with NSCLC are rarely reported in occupational lung cancers, including asbestos-related ones.ALK, ROS1 and RET rearrangements can also be diagnosed in asbestos-related lung cancers http://ow.ly/rFpb30hV5WtWe would like to also acknowledge the pathologists of Brest and the Local tumor tissue biobank BB-0033-00037 (“CRB Santé/Tumorothèque de Brest”) for their collaboration in this study and Miss Sandrine Duigou, Mrs Le Prunennec Annette and Mr Eric Gobin for technical assistance. ER -